PLATELET CELL ADHESION MOLECULES
血小板细胞粘附分子
基本信息
- 批准号:6625303
- 负责人:
- 金额:$ 38.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-12-01 至 2003-11-30
- 项目状态:已结题
- 来源:
- 关键词:Goodpasture's syndrome atherosclerosis bacterial pneumonia binding proteins clinical research disease /disorder model genetically modified animals human subject inflammation laboratory mouse laboratory rabbit leukocyte activation /transformation monocyte neutrophil peritonitis platelet activation platelet aggregation platelets protein kinase protein structure function receptor binding selectins thrombosis wound healing
项目摘要
P-selectin is a cell adhesion molecule that resides in the storage granules of platelets and endothelial cells. Upon cell stimulation, the protein is translocated to the plasma membrane where it functions as a leukocyte receptor for PSGL-1 on neutrophils and monocytes. The current application represents a continuation of studies of the biology of P-selectin and PSGL-1. Since PSGL-1 has been shown to bind to all selectins, the kinetic and equilibrium binding of soluble PSGL-1 to soluble P-selectin, E-selectin and L-selectin will be analyzed by fluorescence spectroscopy. During the past grant period, we have prepared a PSGL-1 deficient mouse by homologous recombination and have completed the initial characterization. Cells from this mouse will be used to establish the physiologic role of PSGL-1 in selectin function by comparing the interaction of PSGL-1 (-/-), (+/-) and (+/+) leukocytes with P-selectin, E- selectin and L-selectin under rolling conditions in a parallel plate ex vivo assay using neutrophils and T lymphocytes. The PSGL-1 deficient mouse and double knockout mice including PSGL-1 null/P-selectin null mice, PSGL-1 null/E-selectin null mice and PSGL-1 null/L-selectin null mice will be employed in model systems to determine the physiologic function of PSGL-1. Pathologic processes to be studied include models of non- immune mediated and T-cell mediated skin inflammation, leukocyte rolling following trauma and TNF, experimental glomerulonephritis, chemical peritonitis, bacterial pneumonitis, thrombosis, atherosclerosis, wound healing and platelet rolling. To understand the molecular basis of signal transduction and effector function induced by platelet activation or P-selectin binding to the P-selectin ligand on leukocytes, the induction of Ca2+ flux in platelets by PSGL-1 via P-selectin will be analyzed. Furthermore, binding of cytoplasmic tails of P-selectin and PSGL-1 to cytoplasmic signalling proteins in platelets and monocytes respectively will be examined using dimer constructs of cytoplasmic tails. If these studies indicate that PSGL-1 and ESL-1 are not physiologically critical counterreceptors for E-selectin or that there is evidence for another P- selectin ligand, we propose to expression clone a novel E-selectin ligand from a leukocyte library prepared from WEHI cells and a novel P-selectin ligand from a library prepared from neutrophils isolated from the PSGL-1 null mouse. The putative ligands will undergo characterization of their full length cDNAs and comparison of their predicted amino acid sequences with that of the PSGL-1, ESL-1 and GlyCAM-1. These studies will contribute to our understanding of the physiologically relevant receptors and counterreceptors that define cell-cell interaction during inflammation.
P-选择素是存在于血小板和内皮细胞的储存颗粒中的细胞粘附分子。在细胞刺激后,蛋白质被转移到质膜,在那里它作为中性粒细胞和单核细胞上PSGL-1的白细胞受体发挥作用。本申请代表了P-选择素和PSGL-1的生物学研究的继续。 由于PSGL-1已显示与所有选择素结合,因此将通过荧光光谱法分析可溶性PSGL-1与可溶性P-选择素、E-选择素和L-选择素的动力学和平衡结合。在过去的资助期内,我们通过同源重组制备了PSGL-1缺陷小鼠,并完成了初步表征。来自该小鼠的细胞将用于通过在使用嗜中性粒细胞和T淋巴细胞的平行板离体测定中在滚动条件下比较PSGL-1(-/-)、(+/-)和(+/+)白细胞与P-选择素、E-选择素和L-选择素的相互作用来确定PSGL-1在选择素功能中的生理作用。PSGL-1缺陷小鼠和双敲除小鼠包括PSGL-1无效/P-选择素无效小鼠、PSGL-1无效/E-选择素无效小鼠和PSGL-1无效/L-选择素无效小鼠将用于模型系统中以确定PSGL-1的生理功能。 待研究的病理过程包括非免疫介导和T细胞介导的皮肤炎症、创伤和TNF后白细胞滚动、实验性肾小球肾炎、化学性腹膜炎、细菌性肺炎、血栓形成、动脉粥样硬化、伤口愈合和血小板滚动的模型。为了理解血小板活化或P-选择素与白细胞上的P-选择素配体结合诱导的信号转导和效应子功能的分子基础,将分析PSGL-1通过P-选择素诱导血小板中的Ca 2+通量。此外,将使用胞质尾的二聚体构建体检查P-选择素和PSGL-1的胞质尾分别与血小板和单核细胞中的胞质信号传导蛋白的结合。如果这些研究表明PSGL-1和ESL-1不是E-选择素的生理学上关键的反受体,或者存在另一种P-选择素配体的证据,我们建议从WEHI细胞制备的白细胞文库表达克隆新的E-选择素配体,并从分离自PSGL-1缺失小鼠的嗜中性粒细胞制备的文库表达克隆新的P-选择素配体。 将对推定的配体进行全长cDNA的表征,并将其预测的氨基酸序列与PSGL-1、ESL-1和GlyCAM-1的氨基酸序列进行比较。这些研究将有助于我们了解生理相关的受体和反受体,定义炎症过程中的细胞-细胞相互作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bruce Furie其他文献
Bruce Furie的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bruce Furie', 18)}}的其他基金
PDI inhibition to prevent thrombosis in humans
PDI 抑制可预防人类血栓形成
- 批准号:
8532976 - 财政年份:2013
- 资助金额:
$ 38.29万 - 项目类别:
Protein disulfide isomerases: A new class of antithrombotic targets
蛋白质二硫键异构酶:一类新的抗血栓靶点
- 批准号:
8532972 - 财政年份:2012
- 资助金额:
$ 38.29万 - 项目类别:
Protein disulfide isomerases: A new class of antithrombotic targets
蛋白质二硫键异构酶:一类新的抗血栓靶点
- 批准号:
8656766 - 财政年份:2012
- 资助金额:
$ 38.29万 - 项目类别:
PDl: Function in thrombus formation and antithrombotic action of inhibitors in m
PDl:m 中抑制剂的血栓形成功能和抗血栓作用
- 批准号:
8401639 - 财政年份:2012
- 资助金额:
$ 38.29万 - 项目类别:
Protein disulfide isomerases: A new class of antithrombotic targets
蛋白质二硫键异构酶:一类新的抗血栓靶点
- 批准号:
8843931 - 财政年份:2012
- 资助金额:
$ 38.29万 - 项目类别:
Protein disulfide isomerases: A new class of antithrombotic targets
蛋白质二硫键异构酶:一类新的抗血栓靶点
- 批准号:
8250091 - 财政年份:2012
- 资助金额:
$ 38.29万 - 项目类别:
Cancer, venous thromboembolic disease and tissue factor-bearing microparticles
癌症、静脉血栓栓塞性疾病和携带组织因子的微粒
- 批准号:
8321526 - 财政年份:2008
- 资助金额:
$ 38.29万 - 项目类别:
Cancer, venous thromboembolic disease and tissue factor-bearing microparticles
癌症、静脉血栓栓塞性疾病和携带组织因子的微粒
- 批准号:
7690929 - 财政年份:2008
- 资助金额:
$ 38.29万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 38.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Epigenetic Regulator Prdm16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk
表观遗传调节因子 Prdm16 控制平滑肌表型调节和动脉粥样硬化风险
- 批准号:
10537602 - 财政年份:2023
- 资助金额:
$ 38.29万 - 项目类别:
Targeted multimodal stimuli-responsive nanogels for atherosclerosis imaging and therapy
用于动脉粥样硬化成像和治疗的靶向多模式刺激响应纳米凝胶
- 批准号:
2880683 - 财政年份:2023
- 资助金额:
$ 38.29万 - 项目类别:
Studentship
Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
- 批准号:
23K15842 - 财政年份:2023
- 资助金额:
$ 38.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
- 批准号:
10652788 - 财政年份:2023
- 资助金额:
$ 38.29万 - 项目类别:
From genotype to phenotype in a GWAS locus: the role of REST in atherosclerosis
GWAS 位点从基因型到表型:REST 在动脉粥样硬化中的作用
- 批准号:
10570469 - 财政年份:2023
- 资助金额:
$ 38.29万 - 项目类别:
Alcohol Regulation of Endothelial Plasticity in Atherosclerosis
酒精对动脉粥样硬化内皮可塑性的调节
- 批准号:
10585070 - 财政年份:2023
- 资助金额:
$ 38.29万 - 项目类别:
The role of extracellular vesicle-associated MicroRNAs in HIV-associated atherosclerosis
细胞外囊泡相关 MicroRNA 在 HIV 相关动脉粥样硬化中的作用
- 批准号:
10619831 - 财政年份:2023
- 资助金额:
$ 38.29万 - 项目类别:
MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS - TOPMED
动脉粥样硬化的多种族研究 - TOPMED
- 批准号:
10974007 - 财政年份:2023
- 资助金额:
$ 38.29万 - 项目类别: